SCFFbw7 Modulates the NFκB Signaling Pathway by Targeting NFκB2 for Ubiquitination and Destruction

Cell Reports

Volumn 1, Issue 5, 2012, Pages 434-443

  Fukushima, Hidefumi ^a   Matsumoto, Akinobu ^b   Inuzuka, Hiroyuki ^a   Zhai, Bo ^a   Lau, Alan W ^a   Wan, Lixin ^a   Gao, Daming ^a   Shaik, Shavali ^a   Yuan, Min ^a   Gygi, Steven P ^a   Jimi, Eijiro ^c   Asara, John M ^a   Nakayama, Keiko ^d   Nakayama, Keiichi I ^b   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU DENTAL COLLEGE   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; NUCLEIC ACID BINDING PROTEIN; PROTEIN P100; PROTEIN SCFFBW7; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CONTROLLED STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; MUTANT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UBIQUITINATION; WILD TYPE;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; F-BOX PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84861668632     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.04.002     Document Type: Article

References (34)

1. Baker R.G., Hayden M.S., Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011, 13:11-22.
2. Basak S., Kim H., Kearns J.D., Tergaonkar V., O'Dea E., Werner S.L., Benedict C.A., Ware C.F., Ghosh G., Verma I.M., Hoffmann A. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007, 128:369-381.
3. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
4. Cardozo T., Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 2004, 5:739-751.
5. Chang C.C., Zhang J., Lombardi L., Neri A., Dalla-Favera R. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol. Cell. Biol. 1995, 15:5180-5187.
6. Cohen S., Achbert-Weiner H., Ciechanover A. Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing. Mol. Cell. Biol. 2004, 24:475-486.
7. Fong A., Sun S.C. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J. Biol. Chem. 2002, 277:22111-22114.
8. Fusco A.J., Savinova O.V., Talwar R., Kearns J.D., Hoffmann A., Ghosh G. Stabilization of RelB requires multidomain interactions with p100/p52. J. Biol. Chem. 2008, 283:12324-12332.
9. Heusch M., Lin L., Geleziunas R., Greene W.C. The generation of nfkb2 p52: mechanism and efficiency. Oncogene 1999, 18:6201-6208.
10. Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol. Rev. 2006, 210:171-186.
11. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
12. Keller U., Huber J., Nilsson J.A., Fallahi M., Hall M.A., Peschel C., Cleveland J.L. Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC Cancer 2010, 10:348.
13. Lawrence T., Bebien M., Liu G.Y., Nizet V., Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005, 434:1138-1143.
14. Legarda-Addison D., Ting A.T. Negative regulation of TCR signaling by NF-kappaB2/p100. J. Immunol. 2007, 178:7767-7778.
15. Maser R.S., Choudhury B., Campbell P.J., Feng B., Wong K.K., Protopopov A., O'Neil J., Gutierrez A., Ivanova E., Perna I., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447:966-971.
16. Matsuoka S., Oike Y., Onoyama I., Iwama A., Arai F., Takubo K., Mashimo Y., Oguro H., Nitta E., Ito K., et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008, 22:986-991.
17. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-κB signaling pathways. Nat. Immunol. 2011, 12:695-708.
18. Onoyama I., Tsunematsu R., Matsumoto A., Kimura T., de Alborán I.M., Nakayama K., Nakayama K.I. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 2007, 204:2875-2888.
19. Rajagopalan H., Jallepalli P.V., Rago C., Velculescu V.E., Kinzler K.W., Vogelstein B., Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428:77-81.
20. Saitoh T., Nakayama M., Nakano H., Yagita H., Yamamoto N., Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J. Biol. Chem. 2003, 278:36005-36012.
21. Sanz A.B., Sanchez-Niño M.D., Izquierdo M.C., Jakubowski A., Justo P., Blanco-Colio L.M., Ruiz-Ortega M., Selgas R., Egido J., Ortiz A. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS ONE 2010, 5:e8955.
22. Shirane M., Hatakeyama S., Hattori K., Nakayama K., Nakayama K. Common pathway for the ubiquitination of IkappaBalpha, IkappaBbeta, and IkappaBepsilon mediated by the F-box protein FWD1. J. Biol. Chem. 1999, 274:28169-28174.
23. Smale S.T. Hierarchies of NF-κB target-gene regulation. Nat. Immunol. 2011, 12:689-694.
24. Spencer E., Jiang J., Chen Z.J. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 1999, 13:284-294.
25. Tucker E., O'Donnell K., Fuchsberger M., Hilton A.A., Metcalf D., Greig K., Sims N.A., Quinn J.M., Alexander W.S., Hilton D.J., et al. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 " super repressor" . J. Immunol. 2007, 179:7514-7522.
26. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27:693-733.
27. Wang Y., Cui H., Schroering A., Ding J.L., Lane W.S., McGill G., Fisher D.E., Ding H.F. NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat. Cell Biol. 2002, 4:888-893.
28. Wei W., Ayad N.G., Wan Y., Zhang G.J., Kirschner M.W., Kaelin W.G. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 2004, 428:194-198.
29. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8:83-93.
30. Welcker M., Orian A., Jin J., Grim J.E., Harper J.W., Eisenman R.N., Clurman B.E. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 2004, 101:9085-9090.
31. Welcker M., Larimore E.A., Frappier L., Clurman B.E. Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol. Cell. Biol. 2011, 31:1214-1224.
32. Wertz I.E., Dixit V.M. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb. Perspect. Biol. 2010, 2:a003350.
33. Xiao G., Harhaj E.W., Sun S.C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 2001, 7:401-409.
34. Yada M., Hatakeyama S., Kamura T., Nishiyama M., Tsunematsu R., Imaki H., Ishida N., Okumura F., Nakayama K., Nakayama K.I. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004, 23:2116-2125.